We also confirmed that at least three independent mechanisms of imatinib resistance arose from a single c-Kit mutant melanoma cell line, and although these resistance effectors displayed differing sensitivity profiles to alternative c-Kit inhibitors, all responded to the concurrent inhibition of MAPK and PI3K signalling. This evidence concerns the gene KIT and melanoma.